Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Life Sciences Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies2
  • 7D2.2%
  • 3M-45.5%
  • 1Y-24.0%
  • YTD-45.7%

Over the last 7 days, the Life Sciences industry has dropped 4.2%, driven by declines from every company within the industry. The industry has fallen 23% in the last year. Looking forward, earnings are forecast to decline by 8.2% per year.

Industry Valuation and Performance

Has the Danish Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026DKK 11.1bDKK 3.1bDKK 1.9b17.5x5.9x3.5x
Fri, 13 Mar 2026DKK 13.0bDKK 3.1bDKK 1.9b21.5x7x4.2x
Sun, 08 Feb 2026DKK 14.2bDKK 3.1bDKK 1.9b23.2x7.4x4.5x
Tue, 06 Jan 2026DKK 20.6bDKK 3.1bDKK 1.9b34.4x10.7x6.6x
Thu, 04 Dec 2025DKK 21.0bDKK 3.1bDKK 1.9b37.5x10.8x6.7x
Sat, 01 Nov 2025DKK 20.8bDKK 3.1bDKK 1.9b38.9x10.8x6.6x
Mon, 29 Sep 2025DKK 17.1bDKK 3.1bDKK 1.9b30.8x8.8x5.4x
Wed, 27 Aug 2025DKK 15.1bDKK 3.1bDKK 1.9b28.3x7.9x4.9x
Fri, 25 Jul 2025DKK 15.8bDKK 725.3mDKK 132.6m53.2x119.5x21.8x
Sun, 22 Jun 2025DKK 17.7bDKK 725.3mDKK 132.6m53.7x133.7x24.4x
Tue, 20 May 2025DKK 15.7bDKK 725.3mDKK 132.6m53.8x118.5x21.7x
Thu, 17 Apr 2025DKK 14.1bDKK 725.3mDKK 132.6m49.3x106.7x19.5x
Sat, 15 Mar 2025DKK 17.5bDKK 725.3mDKK 132.6m54.8x132.3x24.2x
Mon, 10 Feb 2025DKK 20.0bDKK 683.4mDKK 122.6m57.9x163.5x29.3x
Wed, 08 Jan 2025DKK 18.9bDKK 631.7mDKK 89.8m65x211x30x
Fri, 06 Dec 2024DKK 19.9bDKK 631.7mDKK 89.8m61.9x221.9x31.5x
Sun, 03 Nov 2024DKK 14.1bDKK 631.7mDKK 89.8m52.1x157.6x22.4x
Tue, 01 Oct 2024DKK 15.4bDKK 631.7mDKK 89.8m52.1x172.1x24.5x
Thu, 29 Aug 2024DKK 15.6bDKK 625.4mDKK 97.3m45.1x160.5x25x
Sat, 27 Jul 2024DKK 17.2bDKK 606.5mDKK 99.3m46.8x173.5x28.4x
Mon, 24 Jun 2024DKK 13.1bDKK 606.5mDKK 99.3m36.4x132.3x21.7x
Wed, 22 May 2024DKK 11.1bDKK 606.5mDKK 99.3m43.5x112.2x18.4x
Fri, 19 Apr 2024DKK 9.7bDKK 606.5mDKK 99.3m34.8x98x16x
Sun, 17 Mar 2024DKK 11.6bDKK 606.5mDKK 99.3m52.4x117.3x19.2x
Tue, 13 Feb 2024DKK 10.4bDKK 605.1mDKK 136.8m54.6x76.3x17.3x
Thu, 11 Jan 2024DKK 9.1bDKK 647.9mDKK 171.7m39.9x53.3x14.1x
Sat, 09 Dec 2023DKK 8.0bDKK 647.9mDKK 171.7m33.8x46.5x12.3x
Mon, 06 Nov 2023DKK 7.7bDKK 647.9mDKK 171.7m32.7x44.6x11.8x
Wed, 04 Oct 2023DKK 7.5bDKK 647.9mDKK 171.7m31.1x43.5x11.5x
Fri, 01 Sep 2023DKK 9.2bDKK 664.8mDKK 172.7m41x53.3x13.8x
Sun, 30 Jul 2023DKK 9.3bDKK 660.6mDKK 184.0m196.3x50.6x14.1x
Tue, 27 Jun 2023DKK 9.6bDKK 660.6mDKK 184.0m205.4x51.9x14.5x
Thu, 25 May 2023DKK 9.2bDKK 660.6mDKK 184.0m212.9x50.3x14x
Sat, 22 Apr 2023DKK 6.2bDKK 461.2mDKK 179.7m34.7x34.7x13.5x
Price to Earnings Ratio

34.7x


Total Market Cap: DKK 6.2bTotal Earnings: DKK 179.7mTotal Revenue: DKK 461.2mTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Life Sciences Industry Price to Earnings3Y Average 88.9x202420252026
Current Industry PE
    There are only 2 companies in the Danish Life Sciences industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 118% per year over the last three years.
  • Revenues for these companies have grown 89% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market3.76%
Healthcare4.63%
Life Sciences2.18%
Clinical Research and Equipment2.18%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CHEMM ChemoMetecDKK 323.0010.1%
+DKK 515.1m		-34.2%PE31.8x

Latest News

GUBRA
DKK 336.00
Gubra
7D
-4.8%
1Y
-9.7%

GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).
CHEMM
DKK 323.00
ChemoMetec
7D
10.1%
1Y
-34.2%